These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 15676215

  • 1. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
    Casorati G, Locatelli F, Pagani S, Garavaglia C, Montini E, Lisini D, Turin I, Rossi F, Dellabona P, Maccario R, Montagna D.
    Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
    [Abstract] [Full Text] [Related]

  • 2. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
    Morishima Y, Miyamura K, Kojima S, Ueda R, Morishita Y, Sao H, Tanimoto M, Ohno R, Sobue R, Hirano M.
    Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
    [Abstract] [Full Text] [Related]

  • 3. [Reconstitution of peripheral blood lymphocytes in patients treated with bone marrow transplantation: comparison between allogeneic and autologous transplantation].
    Parra C, Roldán E, Rodríguez C, Pérez de Oteyza J, Oteho E, López J, Maldonado MS, García Laraña J, Muñoz A, Odriozola J, Brieva JA.
    Med Clin (Barc); 1999 Jun 12; 113(1):1-5. PubMed ID: 10422068
    [Abstract] [Full Text] [Related]

  • 4. Engraftment of leukocyte subsets following autologous bone marrow transplantation in acute myeloid leukemia using anti-myeloid (CD14 and CD15) monoclonal antibody-purged bone marrow.
    Ericson SG, Colby E, Welch L, Ball ED.
    Bone Marrow Transplant; 1992 Feb 12; 9(2):129-37. PubMed ID: 1373982
    [Abstract] [Full Text] [Related]

  • 5. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N, Douay L, Fouillard L, Laporte JP, Isnard F, Lesage S, Ozsahin H, Bardinet D, Najman A, Gorin NC.
    Bone Marrow Transplant; 1994 Aug 12; 14(2):253-9. PubMed ID: 7994241
    [Abstract] [Full Text] [Related]

  • 6. The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation.
    Newman A, Clutterbuck RD, DeLord C, Powles RL, Catovsky D, Millar JL.
    J Investig Med; 1995 Jun 12; 43(3):269-74. PubMed ID: 7614073
    [Abstract] [Full Text] [Related]

  • 7. Cryopreservation of human bone marrow after purging T-cells or tumor cells.
    Zhang ZX, Xu YJ, Chen Y, Li Y, Shen BF, Bai Y.
    Cryobiology; 1994 Oct 12; 31(5):478-82. PubMed ID: 7988157
    [Abstract] [Full Text] [Related]

  • 8. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
    Atta J, Fauth F, Keyser M, Petershofen E, Weber C, Lippok G, Hoelzer D, Martin H.
    Bone Marrow Transplant; 2000 Jan 12; 25(1):97-104. PubMed ID: 10654022
    [Abstract] [Full Text] [Related]

  • 9. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
    Almici C, Manoni L, Carlo-Stella C, Garau D, Cottafavi L, Rizzoli V.
    Bone Marrow Transplant; 1995 Jul 12; 16(1):95-101. PubMed ID: 7581136
    [Abstract] [Full Text] [Related]

  • 10. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR, Rosenthal C, Elmaagacli AH, Dürig J, Beelen DW, Dührsen U.
    Eur J Haematol; 2004 Jul 12; 73(1):1-9. PubMed ID: 15182331
    [Abstract] [Full Text] [Related]

  • 11. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
    Fauth F, Martin H, Sonnhoff S, Bialleck H, Wiesneth M, Mihanovic B, Hoelzer D.
    Bone Marrow Transplant; 2000 Apr 12; 25(8):831-6. PubMed ID: 10808203
    [Abstract] [Full Text] [Related]

  • 12. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement.
    Grañena A, Castellsagué X, Badell I, Ferra C, Ortega J, Brunet S, Puntí C, Sureda A, Picón M, Valls A, Rutllant M, García J.
    Bone Marrow Transplant; 1999 Sep 12; 24(6):621-7. PubMed ID: 10490727
    [Abstract] [Full Text] [Related]

  • 13. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide.
    Passos-Coelho J, Ross AA, Davis JM, Huelskamp AM, Clarke B, Noga SJ, Davidson NE, Kennedy MJ.
    Cancer Res; 1994 May 01; 54(9):2366-71. PubMed ID: 8162582
    [Abstract] [Full Text] [Related]

  • 14. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia.
    Beaujean F, Bernaudin F, Kuentz M, Lemerle S, Cordonnier C, Le Forestier C, Reinert P, Duedari N, Brandely M, Vernant JP.
    Bone Marrow Transplant; 1995 May 01; 15(5):691-6. PubMed ID: 7670397
    [Abstract] [Full Text] [Related]

  • 15. Autologous PBSC transplant for late onset AML after mafosfamide-purged and TBI-containing autologous BMT.
    Bassan R, Cortelazzo S, Rambaldi A, Cornelli P, Borleri G, Bellavita P, Biondi A, Barbui T.
    Bone Marrow Transplant; 1995 May 01; 15(5):791-3. PubMed ID: 7670409
    [Abstract] [Full Text] [Related]

  • 16. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
    Bierman PJ, Abe F, Buyukberber S, Ino K, Talmadge JE.
    In Vivo; 2000 May 01; 14(1):221-36. PubMed ID: 10757081
    [Abstract] [Full Text] [Related]

  • 17. Restricted TCR repertoire and long-term persistence of donor-derived antigen-experienced CD4+ T cells in allogeneic bone marrow transplantation recipients.
    Vavassori M, Maccario R, Moretta A, Comoli P, Wack A, Locatelli F, Lanzavecchia A, Maserati E, Dellabona P, Casorati G, Montagna D.
    J Immunol; 1996 Dec 15; 157(12):5739-47. PubMed ID: 8955228
    [Abstract] [Full Text] [Related]

  • 18. [Ex-vivo treatment of a bone marrow graft].
    Bieva CJ.
    Rev Med Brux; 1992 May 15; 13(5):177-82. PubMed ID: 1609193
    [Abstract] [Full Text] [Related]

  • 19. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
    Lopez M, Mary JY, Sainteny F.
    Exp Hematol; 1993 Feb 15; 21(2):311-8. PubMed ID: 8425567
    [Abstract] [Full Text] [Related]

  • 20. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
    Arbour S, Toupin S, Bélanger R, Gyger M, Hallé JP, Perreault C, Roy DC.
    Bone Marrow Transplant; 1996 Mar 15; 17(3):315-22. PubMed ID: 8704680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.